Compare EUDA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | SGHT |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Singapore | United States |
| Employees | 117 | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.9M | 187.4M |
| IPO Year | N/A | 2021 |
| Metric | EUDA | SGHT |
|---|---|---|
| Price | $10.80 | $3.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $55.00 | $9.08 |
| AVG Volume (30 Days) | 158.4K | ★ 378.1K |
| Earning Date | 12-19-2023 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $134.73 | $11.81 |
| Revenue Next Year | $195.03 | $10.62 |
| P/E Ratio | $123.62 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.33 | $2.03 |
| 52 Week High | $15.36 | $9.24 |
| Indicator | EUDA | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 78.36 | 38.49 |
| Support Level | $1.53 | $3.29 |
| Resistance Level | N/A | $3.76 |
| Average True Range (ATR) | 0.94 | 0.22 |
| MACD | 0.81 | 0.08 |
| Stochastic Oscillator | 62.36 | 41.43 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.